NEW YORK, Aug. 28 (GenomeWeb News) - Inpharmatica said today that its two-year proteomics collaboration with Serono has been extended for an additional year.
The companies first agreed in mid-2001 to the deal, under which Inpharmatica supplies protein sequences to Serono for its drug target discovery efforts. The arrangement was expandedearlier this year to include additional proprietary genomic sequence data from other protein families.
Inpharmatica said that the extension allows Serono to select an unlimited number of novel proteins from those identified, and noted that it comes about two months after the receipt of a milestone payment from Serono triggered by the development of a novel secreted protein.